nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—SLC6A3—Parkinson's disease	0.3	0.404	CbGaD
Paroxetine—HTR2A—Parkinson's disease	0.172	0.232	CbGaD
Paroxetine—CYP2D6—Parkinson's disease	0.158	0.212	CbGaD
Paroxetine—ABCB1—Parkinson's disease	0.113	0.152	CbGaD
Paroxetine—SLC6A2—locus ceruleus—Parkinson's disease	0.00525	0.0539	CbGeAlD
Paroxetine—TACR1—peripheral nervous system—Parkinson's disease	0.00496	0.0509	CbGeAlD
Paroxetine—HTR2A—enteric nervous system—Parkinson's disease	0.00478	0.049	CbGeAlD
Paroxetine—SLC6A2—sympathetic nervous system—Parkinson's disease	0.00415	0.0426	CbGeAlD
Paroxetine—TACR1—nerve—Parkinson's disease	0.00387	0.0397	CbGeAlD
Paroxetine—HTR2A—myenteric nerve plexus—Parkinson's disease	0.00362	0.0372	CbGeAlD
Paroxetine—HTR2A—locus ceruleus—Parkinson's disease	0.00316	0.0324	CbGeAlD
Paroxetine—SLC6A3—telencephalic ventricle—Parkinson's disease	0.00309	0.0317	CbGeAlD
Paroxetine—SLC6A2—autonomic nervous system—Parkinson's disease	0.00279	0.0286	CbGeAlD
Paroxetine—HTR2A—cerebellar cortex—Parkinson's disease	0.00257	0.0264	CbGeAlD
Paroxetine—HTR2A—sympathetic nervous system—Parkinson's disease	0.00249	0.0256	CbGeAlD
Paroxetine—SLC6A3—nerve—Parkinson's disease	0.00195	0.02	CbGeAlD
Paroxetine—HTR2A—pons—Parkinson's disease	0.00182	0.0187	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—Parkinson's disease	0.00168	0.0172	CbGeAlD
Paroxetine—TACR1—brainstem—Parkinson's disease	0.00166	0.017	CbGeAlD
Paroxetine—TACR1—forebrain—Parkinson's disease	0.0016	0.0164	CbGeAlD
Paroxetine—SLC6A2—nerve—Parkinson's disease	0.00157	0.0161	CbGeAlD
Paroxetine—HTR2A—telencephalic ventricle—Parkinson's disease	0.0015	0.0154	CbGeAlD
Paroxetine—SLC6A3—hindbrain—Parkinson's disease	0.00146	0.0149	CbGeAlD
Paroxetine—SLC6A4—hindbrain—Parkinson's disease	0.00133	0.0137	CbGeAlD
Paroxetine—HTR2A—peripheral nervous system—Parkinson's disease	0.00121	0.0124	CbGeAlD
Paroxetine—TACR1—spinal cord—Parkinson's disease	0.00103	0.0106	CbGeAlD
Paroxetine—HTR2A—nerve—Parkinson's disease	0.000943	0.00968	CbGeAlD
Paroxetine—TACR1—head—Parkinson's disease	0.000917	0.00941	CbGeAlD
Paroxetine—TACR1—nervous system—Parkinson's disease	0.00087	0.00892	CbGeAlD
Paroxetine—CHRM4—head—Parkinson's disease	0.000862	0.00885	CbGeAlD
Paroxetine—TACR1—central nervous system—Parkinson's disease	0.000837	0.00859	CbGeAlD
Paroxetine—SLC6A3—brainstem—Parkinson's disease	0.000835	0.00857	CbGeAlD
Paroxetine—CHRM4—nervous system—Parkinson's disease	0.000818	0.00839	CbGeAlD
Paroxetine—CHRM2—forebrain—Parkinson's disease	0.000808	0.00829	CbGeAlD
Paroxetine—SLC6A3—forebrain—Parkinson's disease	0.000806	0.00827	CbGeAlD
Paroxetine—CHRM4—central nervous system—Parkinson's disease	0.000787	0.00808	CbGeAlD
Paroxetine—SLC6A4—brainstem—Parkinson's disease	0.000765	0.00785	CbGeAlD
Paroxetine—SLC6A4—forebrain—Parkinson's disease	0.000738	0.00758	CbGeAlD
Paroxetine—CHRM1—forebrain—Parkinson's disease	0.000736	0.00755	CbGeAlD
Paroxetine—HTR2A—hindbrain—Parkinson's disease	0.000706	0.00725	CbGeAlD
Paroxetine—CHRM2—cardiovascular system—Parkinson's disease	0.000683	0.00701	CbGeAlD
Paroxetine—CHRM5—head—Parkinson's disease	0.000674	0.00692	CbGeAlD
Paroxetine—SLC6A2—brainstem—Parkinson's disease	0.000674	0.00691	CbGeAlD
Paroxetine—TACR1—brain—Parkinson's disease	0.000665	0.00682	CbGeAlD
Paroxetine—CHRM3—forebrain—Parkinson's disease	0.000658	0.00675	CbGeAlD
Paroxetine—SLC6A2—forebrain—Parkinson's disease	0.00065	0.00667	CbGeAlD
Paroxetine—CYP2D6—hindbrain—Parkinson's disease	0.000644	0.0066	CbGeAlD
Paroxetine—CHRM5—nervous system—Parkinson's disease	0.000639	0.00656	CbGeAlD
Paroxetine—CHRM4—brain—Parkinson's disease	0.000625	0.00641	CbGeAlD
Paroxetine—CHRM1—cardiovascular system—Parkinson's disease	0.000622	0.00638	CbGeAlD
Paroxetine—CHRM5—central nervous system—Parkinson's disease	0.000615	0.00631	CbGeAlD
Paroxetine—SLC6A3—midbrain—Parkinson's disease	0.000532	0.00546	CbGeAlD
Paroxetine—SLC6A3—spinal cord—Parkinson's disease	0.000519	0.00533	CbGeAlD
Paroxetine—CHRM5—brain—Parkinson's disease	0.000489	0.00501	CbGeAlD
Paroxetine—SLC6A4—midbrain—Parkinson's disease	0.000488	0.005	CbGeAlD
Paroxetine—SLC6A4—spinal cord—Parkinson's disease	0.000476	0.00488	CbGeAlD
Paroxetine—SLC6A2—medulla oblongata—Parkinson's disease	0.00047	0.00482	CbGeAlD
Paroxetine—CHRM2—head—Parkinson's disease	0.000463	0.00475	CbGeAlD
Paroxetine—SLC6A3—head—Parkinson's disease	0.000461	0.00473	CbGeAlD
Paroxetine—HTR2A—embryo—Parkinson's disease	0.000442	0.00453	CbGeAlD
Paroxetine—CHRM2—nervous system—Parkinson's disease	0.000439	0.0045	CbGeAlD
Paroxetine—SLC6A3—nervous system—Parkinson's disease	0.000437	0.00449	CbGeAlD
Paroxetine—SLC6A4—head—Parkinson's disease	0.000423	0.00434	CbGeAlD
Paroxetine—CHRM2—central nervous system—Parkinson's disease	0.000422	0.00433	CbGeAlD
Paroxetine—CHRM1—head—Parkinson's disease	0.000421	0.00432	CbGeAlD
Paroxetine—SLC6A3—central nervous system—Parkinson's disease	0.000421	0.00432	CbGeAlD
Paroxetine—SLC6A3—cerebellum—Parkinson's disease	0.000412	0.00422	CbGeAlD
Paroxetine—CYP2B6—cardiovascular system—Parkinson's disease	0.000405	0.00416	CbGeAlD
Paroxetine—HTR2A—brainstem—Parkinson's disease	0.000405	0.00415	CbGeAlD
Paroxetine—CYP2C9—cardiovascular system—Parkinson's disease	0.000401	0.00412	CbGeAlD
Paroxetine—SLC6A4—nervous system—Parkinson's disease	0.000401	0.00411	CbGeAlD
Paroxetine—CHRM1—nervous system—Parkinson's disease	0.000399	0.0041	CbGeAlD
Paroxetine—HTR2A—forebrain—Parkinson's disease	0.000391	0.00401	CbGeAlD
Paroxetine—SLC6A4—central nervous system—Parkinson's disease	0.000386	0.00396	CbGeAlD
Paroxetine—CHRM1—central nervous system—Parkinson's disease	0.000384	0.00394	CbGeAlD
Paroxetine—CHRM3—head—Parkinson's disease	0.000377	0.00387	CbGeAlD
Paroxetine—SLC6A2—head—Parkinson's disease	0.000372	0.00382	CbGeAlD
Paroxetine—CYP2D6—brainstem—Parkinson's disease	0.000369	0.00378	CbGeAlD
Paroxetine—CHRM3—nervous system—Parkinson's disease	0.000357	0.00367	CbGeAlD
Paroxetine—CYP2D6—forebrain—Parkinson's disease	0.000356	0.00365	CbGeAlD
Paroxetine—SLC6A2—nervous system—Parkinson's disease	0.000353	0.00362	CbGeAlD
Paroxetine—CHRM3—central nervous system—Parkinson's disease	0.000344	0.00353	CbGeAlD
Paroxetine—SLC6A2—central nervous system—Parkinson's disease	0.00034	0.00349	CbGeAlD
Paroxetine—CHRM2—brain—Parkinson's disease	0.000335	0.00344	CbGeAlD
Paroxetine—SLC6A3—brain—Parkinson's disease	0.000334	0.00343	CbGeAlD
Paroxetine—HTR2A—cardiovascular system—Parkinson's disease	0.00033	0.00339	CbGeAlD
Paroxetine—SLC6A4—brain—Parkinson's disease	0.000306	0.00314	CbGeAlD
Paroxetine—CHRM1—brain—Parkinson's disease	0.000305	0.00313	CbGeAlD
Paroxetine—ABCB1—embryo—Parkinson's disease	0.00029	0.00297	CbGeAlD
Paroxetine—HTR2A—medulla oblongata—Parkinson's disease	0.000282	0.0029	CbGeAlD
Paroxetine—CYP2B6—head—Parkinson's disease	0.000274	0.00281	CbGeAlD
Paroxetine—CHRM3—brain—Parkinson's disease	0.000273	0.0028	CbGeAlD
Paroxetine—SLC6A2—brain—Parkinson's disease	0.00027	0.00277	CbGeAlD
Paroxetine—CYP2B6—nervous system—Parkinson's disease	0.00026	0.00267	CbGeAlD
Paroxetine—HTR2A—midbrain—Parkinson's disease	0.000258	0.00265	CbGeAlD
Paroxetine—ABCB1—forebrain—Parkinson's disease	0.000256	0.00263	CbGeAlD
Paroxetine—HTR2A—spinal cord—Parkinson's disease	0.000252	0.00258	CbGeAlD
Paroxetine—CYP2B6—central nervous system—Parkinson's disease	0.00025	0.00257	CbGeAlD
Paroxetine—HTR2A—head—Parkinson's disease	0.000224	0.0023	CbGeAlD
Paroxetine—CYP2C8—brain—Parkinson's disease	0.000222	0.00227	CbGeAlD
Paroxetine—ABCB1—cardiovascular system—Parkinson's disease	0.000217	0.00222	CbGeAlD
Paroxetine—HTR2A—nervous system—Parkinson's disease	0.000212	0.00218	CbGeAlD
Paroxetine—HTR2A—central nervous system—Parkinson's disease	0.000204	0.0021	CbGeAlD
Paroxetine—CYP2D6—head—Parkinson's disease	0.000204	0.00209	CbGeAlD
Paroxetine—HTR2A—cerebellum—Parkinson's disease	0.0002	0.00205	CbGeAlD
Paroxetine—CYP2B6—brain—Parkinson's disease	0.000199	0.00204	CbGeAlD
Paroxetine—CYP2D6—nervous system—Parkinson's disease	0.000193	0.00198	CbGeAlD
Paroxetine—CYP2D6—central nervous system—Parkinson's disease	0.000186	0.00191	CbGeAlD
Paroxetine—ABCB1—medulla oblongata—Parkinson's disease	0.000185	0.0019	CbGeAlD
Paroxetine—CYP2D6—cerebellum—Parkinson's disease	0.000182	0.00187	CbGeAlD
Paroxetine—ABCB1—midbrain—Parkinson's disease	0.000169	0.00173	CbGeAlD
Paroxetine—ABCB1—spinal cord—Parkinson's disease	0.000165	0.00169	CbGeAlD
Paroxetine—HTR2A—brain—Parkinson's disease	0.000162	0.00166	CbGeAlD
Paroxetine—CYP2D6—brain—Parkinson's disease	0.000148	0.00152	CbGeAlD
Paroxetine—ABCB1—head—Parkinson's disease	0.000147	0.0015	CbGeAlD
Paroxetine—ABCB1—nervous system—Parkinson's disease	0.000139	0.00143	CbGeAlD
Paroxetine—ABCB1—central nervous system—Parkinson's disease	0.000134	0.00137	CbGeAlD
Paroxetine—ABCB1—cerebellum—Parkinson's disease	0.000131	0.00134	CbGeAlD
Paroxetine—ABCB1—brain—Parkinson's disease	0.000106	0.00109	CbGeAlD
Paroxetine—HTR2A—GPCR downstream signaling—EDN1—Parkinson's disease	1.46e-05	9.1e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTA4—Parkinson's disease	1.45e-05	9.07e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—EDN1—Parkinson's disease	1.45e-05	9.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—EDN1—Parkinson's disease	1.45e-05	9.02e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR7—Parkinson's disease	1.44e-05	8.99e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD2—Parkinson's disease	1.44e-05	8.99e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.44e-05	8.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—EDN1—Parkinson's disease	1.43e-05	8.93e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRBK1—Parkinson's disease	1.42e-05	8.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.39e-05	8.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.38e-05	8.62e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD2—Parkinson's disease	1.38e-05	8.61e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR7—Parkinson's disease	1.38e-05	8.61e-05	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.38e-05	8.59e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGF20—Parkinson's disease	1.37e-05	8.57e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGF20—Parkinson's disease	1.37e-05	8.52e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGF20—Parkinson's disease	1.36e-05	8.49e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGF20—Parkinson's disease	1.35e-05	8.41e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DDC—Parkinson's disease	1.34e-05	8.37e-05	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	1.33e-05	8.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADORA2A—Parkinson's disease	1.33e-05	8.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EDN1—Parkinson's disease	1.32e-05	8.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADORA2A—Parkinson's disease	1.32e-05	8.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP2D6—Parkinson's disease	1.32e-05	8.25e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADORA2A—Parkinson's disease	1.32e-05	8.24e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EDN1—Parkinson's disease	1.32e-05	8.22e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EDN1—Parkinson's disease	1.31e-05	8.19e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PLA2G6—Parkinson's disease	1.31e-05	8.17e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADORA2A—Parkinson's disease	1.31e-05	8.16e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EDN1—Parkinson's disease	1.3e-05	8.11e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CASP3—Parkinson's disease	1.3e-05	8.11e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CTGF—Parkinson's disease	1.3e-05	8.1e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MAOB—Parkinson's disease	1.3e-05	8.09e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—Parkinson's disease	1.29e-05	8.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—HTR2A—Parkinson's disease	1.27e-05	7.92e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTA4—Parkinson's disease	1.27e-05	7.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—HTR2A—Parkinson's disease	1.26e-05	7.89e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DDC—Parkinson's disease	1.26e-05	7.89e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DDC—Parkinson's disease	1.25e-05	7.82e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—HTR2A—Parkinson's disease	1.25e-05	7.82e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.23e-05	7.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INSR—Parkinson's disease	1.23e-05	7.67e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INSR—Parkinson's disease	1.22e-05	7.62e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INSR—Parkinson's disease	1.22e-05	7.6e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP2E1—Parkinson's disease	1.21e-05	7.55e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF2—Parkinson's disease	1.21e-05	7.54e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INSR—Parkinson's disease	1.21e-05	7.53e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NQO1—Parkinson's disease	1.2e-05	7.46e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MAPK8—Parkinson's disease	1.19e-05	7.46e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	1.19e-05	7.45e-05	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	1.19e-05	7.43e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTA4—Parkinson's disease	1.18e-05	7.39e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TH—Parkinson's disease	1.18e-05	7.36e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	1.17e-05	7.29e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1R—Parkinson's disease	1.17e-05	7.29e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGB—Parkinson's disease	1.16e-05	7.24e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF2—Parkinson's disease	1.16e-05	7.22e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HTR1A—Parkinson's disease	1.15e-05	7.21e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGB—Parkinson's disease	1.15e-05	7.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EDN1—Parkinson's disease	1.15e-05	7.2e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HTR2A—Parkinson's disease	1.15e-05	7.19e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGB—Parkinson's disease	1.15e-05	7.18e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR1A—Parkinson's disease	1.15e-05	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HTR2A—Parkinson's disease	1.15e-05	7.17e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR1A—Parkinson's disease	1.14e-05	7.15e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLA2G6—Parkinson's disease	1.14e-05	7.12e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGB—Parkinson's disease	1.14e-05	7.11e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP2D6—Parkinson's disease	1.14e-05	7.1e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TAC1—Parkinson's disease	1.14e-05	7.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HTR2A—Parkinson's disease	1.14e-05	7.1e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR1A—Parkinson's disease	1.13e-05	7.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYCS—Parkinson's disease	1.13e-05	7.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TAC1—Parkinson's disease	1.13e-05	7.06e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MAOB—Parkinson's disease	1.13e-05	7.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TAC1—Parkinson's disease	1.13e-05	7.04e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1R—Parkinson's disease	1.12e-05	6.98e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CTGF—Parkinson's disease	1.12e-05	6.97e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TAC1—Parkinson's disease	1.12e-05	6.97e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD1—Parkinson's disease	1.12e-05	6.96e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD1—Parkinson's disease	1.11e-05	6.92e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD1—Parkinson's disease	1.11e-05	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EDN1—Parkinson's disease	1.1e-05	6.9e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD1—Parkinson's disease	1.09e-05	6.83e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD3—Parkinson's disease	1.08e-05	6.74e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	1.07e-05	6.71e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD3—Parkinson's disease	1.07e-05	6.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD3—Parkinson's disease	1.07e-05	6.68e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLA2G6—Parkinson's disease	1.07e-05	6.65e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MAOB—Parkinson's disease	1.06e-05	6.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD3—Parkinson's disease	1.06e-05	6.62e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NGF—Parkinson's disease	1.06e-05	6.62e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MAOB—Parkinson's disease	1.05e-05	6.58e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP2E1—Parkinson's disease	1.04e-05	6.49e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NQO1—Parkinson's disease	1.03e-05	6.42e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NGF—Parkinson's disease	1.02e-05	6.34e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TH—Parkinson's disease	1.01e-05	6.33e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HTR2A—Parkinson's disease	1.01e-05	6.3e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRBK1—Parkinson's disease	1.01e-05	6.29e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1e-05	6.26e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRBK1—Parkinson's disease	1e-05	6.26e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—COMT—Parkinson's disease	1e-05	6.25e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRBK1—Parkinson's disease	1e-05	6.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTP1—Parkinson's disease	9.97e-06	6.23e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MAOA—Parkinson's disease	9.95e-06	6.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRBK1—Parkinson's disease	9.9e-06	6.18e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—HMOX1—Parkinson's disease	9.84e-06	6.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD2—Parkinson's disease	9.77e-06	6.1e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HTR7—Parkinson's disease	9.77e-06	6.1e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYCS—Parkinson's disease	9.73e-06	6.08e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR7—Parkinson's disease	9.72e-06	6.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD2—Parkinson's disease	9.72e-06	6.06e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR7—Parkinson's disease	9.68e-06	6.04e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD2—Parkinson's disease	9.68e-06	6.04e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HTR2A—Parkinson's disease	9.66e-06	6.03e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	9.63e-06	6.01e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR7—Parkinson's disease	9.59e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD2—Parkinson's disease	9.59e-06	5.99e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CTGF—Parkinson's disease	9.45e-06	5.9e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ABCB1—Parkinson's disease	9.44e-06	5.89e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—APOE—Parkinson's disease	9.38e-06	5.86e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTM1—Parkinson's disease	9.17e-06	5.72e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—Parkinson's disease	8.98e-06	5.61e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	8.81e-06	5.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—Parkinson's disease	8.78e-06	5.48e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NQO1—Parkinson's disease	8.71e-06	5.44e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—COMT—Parkinson's disease	8.62e-06	5.38e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TH—Parkinson's disease	8.58e-06	5.36e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTP1—Parkinson's disease	8.58e-06	5.36e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MAOA—Parkinson's disease	8.56e-06	5.34e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—HMOX1—Parkinson's disease	8.46e-06	5.28e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP2D6—Parkinson's disease	8.39e-06	5.24e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYCS—Parkinson's disease	8.24e-06	5.14e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CTGF—Parkinson's disease	8.24e-06	5.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF2—Parkinson's disease	8.19e-06	5.11e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF2—Parkinson's disease	8.14e-06	5.08e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ABCB1—Parkinson's disease	8.12e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF2—Parkinson's disease	8.12e-06	5.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—Parkinson's disease	8.1e-06	5.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF2—Parkinson's disease	8.04e-06	5.02e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—INS—Parkinson's disease	8.01e-06	5e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—Parkinson's disease	7.91e-06	4.94e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTM1—Parkinson's disease	7.89e-06	4.92e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—Parkinson's disease	7.87e-06	4.91e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—Parkinson's disease	7.85e-06	4.9e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2D6—Parkinson's disease	7.84e-06	4.89e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EDN1—Parkinson's disease	7.82e-06	4.88e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EDN1—Parkinson's disease	7.78e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—Parkinson's disease	7.77e-06	4.85e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CTGF—Parkinson's disease	7.76e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EDN1—Parkinson's disease	7.75e-06	4.84e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CTGF—Parkinson's disease	7.69e-06	4.8e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EDN1—Parkinson's disease	7.68e-06	4.79e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—INS—Parkinson's disease	7.68e-06	4.79e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP2E1—Parkinson's disease	7.67e-06	4.79e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—Parkinson's disease	7.63e-06	4.76e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NQO1—Parkinson's disease	7.59e-06	4.74e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—Parkinson's disease	7.55e-06	4.71e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—Parkinson's disease	7.54e-06	4.71e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TH—Parkinson's disease	7.48e-06	4.67e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—COMT—Parkinson's disease	7.3e-06	4.56e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTP1—Parkinson's disease	7.26e-06	4.53e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MAOA—Parkinson's disease	7.25e-06	4.52e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	7.23e-06	4.51e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NGF—Parkinson's disease	7.19e-06	4.49e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYCS—Parkinson's disease	7.18e-06	4.48e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2E1—Parkinson's disease	7.17e-06	4.47e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HMOX1—Parkinson's disease	7.16e-06	4.47e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NQO1—Parkinson's disease	7.15e-06	4.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NGF—Parkinson's disease	7.15e-06	4.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NGF—Parkinson's disease	7.13e-06	4.45e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NQO1—Parkinson's disease	7.09e-06	4.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NGF—Parkinson's disease	7.06e-06	4.4e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TH—Parkinson's disease	7.05e-06	4.4e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TH—Parkinson's disease	6.99e-06	4.36e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—Parkinson's disease	6.97e-06	4.35e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCB1—Parkinson's disease	6.88e-06	4.29e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—Parkinson's disease	6.8e-06	4.25e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—Parkinson's disease	6.78e-06	4.23e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYCS—Parkinson's disease	6.77e-06	4.22e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—Parkinson's disease	6.72e-06	4.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYCS—Parkinson's disease	6.71e-06	4.19e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—Parkinson's disease	6.68e-06	4.17e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—Parkinson's disease	6.49e-06	4.05e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—INS—Parkinson's disease	6.44e-06	4.02e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—Parkinson's disease	6.39e-06	3.99e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—Parkinson's disease	6.36e-06	3.97e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—COMT—Parkinson's disease	6.36e-06	3.97e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTP1—Parkinson's disease	6.33e-06	3.95e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—Parkinson's disease	6.33e-06	3.95e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MAOA—Parkinson's disease	6.31e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—Parkinson's disease	6.31e-06	3.94e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—Parkinson's disease	6.24e-06	3.9e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—Parkinson's disease	6.24e-06	3.9e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—COMT—Parkinson's disease	5.99e-06	3.74e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—Parkinson's disease	5.97e-06	3.72e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	5.96e-06	3.72e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MAOA—Parkinson's disease	5.95e-06	3.71e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—COMT—Parkinson's disease	5.94e-06	3.71e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—Parkinson's disease	5.93e-06	3.7e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTP1—Parkinson's disease	5.91e-06	3.69e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—Parkinson's disease	5.9e-06	3.68e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MAOA—Parkinson's disease	5.9e-06	3.68e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	5.88e-06	3.67e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—Parkinson's disease	5.83e-06	3.64e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—Parkinson's disease	5.82e-06	3.63e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—Parkinson's disease	5.71e-06	3.57e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—Parkinson's disease	5.68e-06	3.54e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	5.65e-06	3.52e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—Parkinson's disease	5.6e-06	3.49e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—Parkinson's disease	5.57e-06	3.48e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—INS—Parkinson's disease	5.54e-06	3.46e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—Parkinson's disease	5.49e-06	3.43e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK8—Parkinson's disease	5.48e-06	3.42e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	5.48e-06	3.42e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—INS—Parkinson's disease	5.43e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—Parkinson's disease	5.43e-06	3.39e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—INS—Parkinson's disease	5.4e-06	3.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—INS—Parkinson's disease	5.39e-06	3.36e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—INS—Parkinson's disease	5.33e-06	3.33e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK8—Parkinson's disease	5.25e-06	3.28e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—Parkinson's disease	5.25e-06	3.28e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—Parkinson's disease	5.2e-06	3.25e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—Parkinson's disease	5.14e-06	3.21e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	4.84e-06	3.02e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—Parkinson's disease	4.8e-06	3e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—Parkinson's disease	4.79e-06	2.99e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—INS—Parkinson's disease	4.69e-06	2.93e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—Parkinson's disease	4.51e-06	2.81e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—Parkinson's disease	4.47e-06	2.79e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—INS—Parkinson's disease	4.09e-06	2.55e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—Parkinson's disease	4.05e-06	2.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—Parkinson's disease	4.02e-06	2.51e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—Parkinson's disease	4.02e-06	2.51e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—Parkinson's disease	4.01e-06	2.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—Parkinson's disease	4e-06	2.5e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—Parkinson's disease	3.98e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—Parkinson's disease	3.97e-06	2.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—Parkinson's disease	3.95e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—INS—Parkinson's disease	3.85e-06	2.4e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—INS—Parkinson's disease	3.82e-06	2.38e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK8—Parkinson's disease	3.72e-06	2.32e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK8—Parkinson's disease	3.7e-06	2.31e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK8—Parkinson's disease	3.69e-06	2.3e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK8—Parkinson's disease	3.65e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—Parkinson's disease	3.5e-06	2.19e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—Parkinson's disease	3.35e-06	2.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—Parkinson's disease	2.37e-06	1.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—Parkinson's disease	2.36e-06	1.47e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—Parkinson's disease	2.35e-06	1.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—Parkinson's disease	2.33e-06	1.45e-05	CbGpPWpGaD
